[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI1504108T1 - Lentiviralni vektor - Google Patents

Lentiviralni vektor

Info

Publication number
SI1504108T1
SI1504108T1 SI200332266T SI200332266T SI1504108T1 SI 1504108 T1 SI1504108 T1 SI 1504108T1 SI 200332266 T SI200332266 T SI 200332266T SI 200332266 T SI200332266 T SI 200332266T SI 1504108 T1 SI1504108 T1 SI 1504108T1
Authority
SI
Slovenia
Prior art keywords
lentiviral vector
lentiviral
vector
Prior art date
Application number
SI200332266T
Other languages
English (en)
Inventor
Philippa Radcliffe
James E. Miskin
Fraser J. Wilkes
Kyriacos A. Mitrophanous
Original Assignee
Oxford Biomedica (Uk) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0202403A external-priority patent/GB0202403D0/en
Priority claimed from GB0212768A external-priority patent/GB0212768D0/en
Application filed by Oxford Biomedica (Uk) Limited filed Critical Oxford Biomedica (Uk) Limited
Publication of SI1504108T1 publication Critical patent/SI1504108T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16041Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/001Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/15Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/50Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/60Vector systems having a special element relevant for transcription from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
SI200332266T 2002-02-01 2003-02-03 Lentiviralni vektor SI1504108T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0202403A GB0202403D0 (en) 2002-02-01 2002-02-01 Method
GB0212768A GB0212768D0 (en) 2002-05-31 2002-05-31 Method
PCT/GB2003/000418 WO2003064665A2 (en) 2002-02-01 2003-02-03 Viral vector
EP03734767.1A EP1504108B1 (en) 2002-02-01 2003-02-03 Lentiviral vector

Publications (1)

Publication Number Publication Date
SI1504108T1 true SI1504108T1 (sl) 2013-07-31

Family

ID=27665368

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200332266T SI1504108T1 (sl) 2002-02-01 2003-02-03 Lentiviralni vektor

Country Status (9)

Country Link
EP (2) EP1504108B1 (sl)
JP (2) JP4598398B2 (sl)
AU (1) AU2003238456A1 (sl)
CY (1) CY1114192T1 (sl)
DK (2) DK1504108T3 (sl)
ES (2) ES2634424T3 (sl)
PT (1) PT1504108E (sl)
SI (1) SI1504108T1 (sl)
WO (1) WO2003064665A2 (sl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1504108T1 (sl) * 2002-02-01 2013-07-31 Oxford Biomedica (Uk) Limited Lentiviralni vektor
US10000757B2 (en) 2005-05-27 2018-06-19 Ospedale San Raffaele S.R.L. Gene vector
US20080220471A1 (en) * 2005-07-27 2008-09-11 Genentech, Inc. Vectors and Methods Using Same
EP1929021A2 (en) * 2005-08-31 2008-06-11 Genvec, Inc. Adenoviral vector-based malaria vaccines
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
JP5559185B2 (ja) * 2008-11-11 2014-07-23 オックスフォード バイオメディカ(ユーケー)リミテッド 方法
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
GB201318804D0 (en) * 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
CA2966620A1 (en) 2014-11-05 2016-05-12 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
MX2017006217A (es) 2014-11-14 2018-05-02 Voyager Therapeutics Inc Polinucleotidos moduladores.
GB2540786A (en) * 2015-07-28 2017-02-01 Glaxosmithkline Ip Dev Ltd Codon optimised tet repressor proteins
PT3380620T (pt) 2015-11-23 2024-09-03 Novartis Ag Vetores de transferência lentivirais otimizados e suas utilizações
CN108291211A (zh) 2015-11-24 2018-07-17 葛兰素史密斯克莱知识产权发展有限公司 用于产生逆转录病毒的瞬时转染方法
RU2752498C2 (ru) * 2015-11-24 2021-07-28 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Стабильные клеточные линии для продуцирования ретровирусов
CA3024448A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Modulatory polynucleotides
US11427645B2 (en) 2017-03-15 2022-08-30 Oxford Biomedica (Uk) Limited 5T4-targeting agents and methods
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
EP3502260A1 (en) 2017-12-22 2019-06-26 Oxford BioMedica (UK) Limited Retroviral vector
JP2021533831A (ja) * 2018-08-16 2021-12-09 スペースクラフト セブン リミテッド ライアビリティ カンパニー ウイルスベクターのための生成方法
WO2020106621A1 (en) * 2018-11-19 2020-05-28 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
US20220175962A1 (en) 2019-03-10 2022-06-09 Sio Gene Therapies Inc. Gene therapy compositions and methods for treating parkinson's disease
WO2021094752A1 (en) 2019-11-12 2021-05-20 Oxford Biomedica (Uk) Limited Production system
EP4103723A1 (en) 2020-02-13 2022-12-21 Oxford BioMedica (UK) Limited Production of lentiviral vectors
US20230118587A1 (en) 2020-03-13 2023-04-20 Oxford Biomedica (Uk) Limited Lentiviral Vectors
JP2023515711A (ja) 2020-04-27 2023-04-13 ユニヴァーシティ オブ アイオワ リサーチ ファウンデーション 組成物および嚢胞性線維症の処置のための方法
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
IL300219A (en) * 2020-08-03 2023-03-01 Prevail Therapeutics Inc Parkin-encoding AAV vectors and uses thereof
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6075190A (en) 1989-06-30 1991-01-17 Regents Of The University Of California, The Retrovirus detection
CA2092195C (en) 1990-09-21 2000-04-18 Douglas J. Jolly Retroviral packaging cell line
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
DK0758397T3 (da) 1994-04-29 2005-10-10 Baxter Healthcare Sa Rekombinante poxvira med fremmede polynucleotider i essentielle regioner
WO1996009400A1 (en) 1994-09-19 1996-03-28 Systemix, Inc. Methods for genetically modifying hematopoietic stem cells
WO1996017053A1 (en) 1994-11-28 1996-06-06 Genetic Therapy, Inc. Vectors for tissue-specific replication
GB9510272D0 (en) 1995-05-22 1995-07-19 Isis Innovation Retroviral vectors
DE69634606D1 (de) 1995-10-16 2005-05-19 Dana Farber Cancer Inst Inc Neue expressionsvektoren und verfahren zu deren verwendung
WO1997017457A2 (en) 1995-11-08 1997-05-15 Whitehead Institute For Biomedical Research Stable packaging cell line producing pseudotyped retroviruses
US5739018A (en) 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
US6133027A (en) 1996-08-07 2000-10-17 City Of Hope Inducible expression system
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
WO1998017815A1 (en) 1996-10-17 1998-04-30 Oxford Biomedica (Uk) Limited Retroviral vectors
WO1999061639A2 (en) 1998-05-22 1999-12-02 Oxford Biomedica (Uk) Limited Retroviral delivery system
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
JP4578678B2 (ja) 1997-12-22 2010-11-10 オックスフォード バイオメディカ(ユーケー)リミテッド ウマ伝染性貧血ウイルス(eiav)系
WO1999040930A1 (en) 1998-02-12 1999-08-19 Center For Blood Research, Inc. Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
AU763020B2 (en) 1998-03-06 2003-07-10 Oxford Biomedica (Uk) Limited Enhanced prodrug activation
ATE407206T1 (de) 1998-11-10 2008-09-15 Univ Rochester Methoden zu herstellung von genbanken
ATE293690T1 (de) 1998-11-18 2005-05-15 Oxford Biomedica Ltd Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
GB9912965D0 (en) 1999-06-03 1999-08-04 Oxford Biomedica Ltd In vivo selection method
GB0009760D0 (en) * 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
GB0024550D0 (sl) * 2000-10-06 2000-11-22 Oxford Biomedica Ltd
SI1504108T1 (sl) * 2002-02-01 2013-07-31 Oxford Biomedica (Uk) Limited Lentiviralni vektor

Also Published As

Publication number Publication date
EP2348119A2 (en) 2011-07-27
EP2348119A3 (en) 2011-11-02
DK2348119T3 (en) 2017-08-21
EP2348119B1 (en) 2017-04-26
JP2010263904A (ja) 2010-11-25
EP1504108A2 (en) 2005-02-09
ES2411981T3 (es) 2013-07-09
JP5601898B2 (ja) 2014-10-08
AU2003238456A1 (en) 2003-09-02
JP4598398B2 (ja) 2010-12-15
WO2003064665A2 (en) 2003-08-07
JP2005515783A (ja) 2005-06-02
PT1504108E (pt) 2013-06-12
DK1504108T3 (da) 2013-06-10
WO2003064665A3 (en) 2004-12-02
CY1114192T1 (el) 2016-08-31
ES2634424T3 (es) 2017-09-27
EP1504108B1 (en) 2013-04-17

Similar Documents

Publication Publication Date Title
SI1504108T1 (sl) Lentiviralni vektor
GB2392460B (en) Delayed-gelation solution
AU2003249738A8 (en) Ostoscope
AU2003297193A8 (en) Meta-web
AU2003252028A8 (en) Heterodiamondoids
AU2003279495A8 (en) Alert-modeling
GB0212891D0 (en) Jewllery case
AU2003299142A8 (en) Waveless hull
GB0213765D0 (en) Admixture
PL378060A1 (pl) Nowy wektor
AU2003264900A8 (en) Cast-cutter
AU2002367810A8 (en) Bis-transition-metal-chelate-probes
EP1616957A4 (en) VECTOR
AU2002341221A8 (en) Honey-brandy
AU2003253735A8 (en) Vacuolins
GB0226711D0 (en) Lentiviral vectors
EP1574454A4 (en) CASING
GB0209023D0 (en) Expression vector
EP1564156A4 (en) BOX
AU2326P (en) Gavol Gazania rigens
AU2328P (en) Archley Arctotis fastuosa
AU2327P (en) Archnah Arctotis fastuosa
GB0215462D0 (en) Vessels
GB0228314D0 (en) Vector system
GB0318213D0 (en) Vector system